Trade Report: Today, 69,743 Shares of BioMarin Pharmaceutical Inc. (BMRN) Stock are sold by Jean Jacques Bienaime

Today, 69,743 Shares of BioMarin Pharmaceutical Inc. (BMRN) Stock are sold by Jean Jacques Bienaime

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 69,743 shares of the company’s stock in a transaction that occurred on Tuesday, November 22nd. The shares were sold at an average price of $85.69, for a total transaction of $5,976,277.67. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Jean Jacques Bienaime also recently made the following trade(s): On Monday, November 21st, Jean Jacques Bienaime sold 69,744 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $87.56, for a total transaction of $6,106,784.64. On Monday, November 7th, Jean Jacques Bienaime sold 70,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $82.52, for a total transaction of $5,776,400.00. On Tuesday, November 8th, Jean Jacques Bienaime sold 140,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $82.67, for a total transaction of $11,573,800.00. On Friday, October 28th, Jean Jacques Bienaime sold 120,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $81.30, for a total transaction of $9,756,000.00. On Monday, October 17th, Jean Jacques Bienaime sold 41,666 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $84.39, for a total transaction of $3,516,193.74. On Friday, October 14th, Jean Jacques Bienaime sold 64,125 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $86.96, for a total transaction of $5,576,310.00. On Thursday, September 29th, Jean Jacques Bienaime sold 53,125 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $93.65, for a total transaction of $4,975,156.25. On Friday, September 16th, Jean Jacques Bienaime sold 137,368 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $95.34, for a total transaction of $13,096,665.12.

Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) opened at 88.10 on Friday. The firm’s 50-day moving average is $86.66 and its 200-day moving average is $89.49. The firm’s market capitalization is $15.15 billion. BioMarin Pharmaceutical Inc. has a 52 week low of $62.12 and a 52 week high of $107.56.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its earnings results on Thursday, October 27th. The company reported ($0.26) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.39) by $0.13. The company had revenue of $279.90 million for the quarter, compared to analysts’ expectations of $289.70 million. BioMarin Pharmaceutical had a negative return on equity of 8.54% and a negative net margin of 46.22%. The business’s revenue for the quarter was up 34.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.60) EPS. Equities analysts anticipate that BioMarin Pharmaceutical Inc. will post ($3.73) EPS for the current year.

Several research analysts have recently weighed in on BMRN shares. Goldman Sachs Group Inc. upgraded shares of BioMarin Pharmaceutical to a “neutral” rating in a report on Friday, October 7th. Leerink Swann reissued an “outperform” rating and issued a $127.00 price objective on shares of BioMarin Pharmaceutical in a research report on Friday, September 16th. Piper Jaffray Cos. reissued an “overweight” rating on shares of BioMarin Pharmaceutical in a research report on Friday, August 19th. Vetr raised shares of BioMarin Pharmaceutical from a “buy” rating to a “strong-buy” rating and set a $111.64 price objective on the stock in a research report on Wednesday, August 24th. Finally, Wedbush reissued a “neutral” rating and issued a $104.00 price objective (up previously from $102.00) on shares of BioMarin Pharmaceutical in a research report on Friday, October 28th. Five investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. BioMarin Pharmaceutical presently has a consensus rating of “Buy” and an average price target of $115.24.

Large investors have recently added to or reduced their stakes in the company. Cornerstone Advisors Inc. boosted its stake in BioMarin Pharmaceutical by 22.0% in the third quarter. Cornerstone Advisors Inc. now owns 1,159 shares of the company’s stock worth $107,000 after buying an additional 209 shares during the last quarter. Independent Portfolio Consultants Inc. acquired a new stake in BioMarin Pharmaceutical during the third quarter worth approximately $121,000. Toronto Dominion Bank boosted its stake in BioMarin Pharmaceutical by 57.8% in the third quarter. Toronto Dominion Bank now owns 1,401 shares of the company’s stock worth $130,000 after buying an additional 513 shares during the last quarter. Rockefeller Financial Services Inc. acquired a new stake in BioMarin Pharmaceutical during the second quarter worth approximately $111,000. Finally, Meeder Asset Management Inc. acquired a new stake in BioMarin Pharmaceutical during the second quarter worth approximately $140,000. Institutional investors own 93.68% of the company’s stock.

BioMarin Pharmaceutical Company Profile

Related posts

Leave a Comment